Autophagy Inducers in Neurodegeneration

Migration, Crosslink

📖

Autophagy Inducers in Neurodegeneration

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-autophagy-inducers-neu

📖 Wiki Page

therapeutic1618 wordssynced 2026-04-02

Autophagy Inducers in Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Autophagy Inducers in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">[mTOR](/mechanisms/mtor-signaling-pathway) inhibitors</td>
<td>Rapamycin, Everolimus</td>
</tr>
<tr>
<td class="label">mTOR-independent</td>
<td>Trehalose, Carbamazepine</td>
</tr>
<tr>
<td class="label">AMPK activators</td>
<td>Metformin, Resveratrol</td>
</tr>
<tr>
<td class="label">TFEB activators</td>
<td>Genistein, Daidzein</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin (Sirolimus)</td>
<td>mTORC1 inhibitor</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>mTORC1 inhibitor</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>mTOR-independent</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>AMPK activator</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>mTOR-independent + [GSK-3β](/entities/gsk3-beta)</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>AMPK/SIRT1 activator</td>
</tr>
<tr>
<td class="label">Carbamazepine</td>
<td>mTOR-independent</td>
</tr>
<tr>
<td class="label">Nicotinamide</td>
<td>SIRT1 activator</td>
</tr>
<tr>
<td class="label">Genistein</td>
<td>TFEB activator</td>
</tr>
<tr>
<td class="label">Laquinimod</td>
<td>

...

Autophagy Inducers in Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Autophagy Inducers in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">[mTOR](/mechanisms/mtor-signaling-pathway) inhibitors</td>
<td>Rapamycin, Everolimus</td>
</tr>
<tr>
<td class="label">mTOR-independent</td>
<td>Trehalose, Carbamazepine</td>
</tr>
<tr>
<td class="label">AMPK activators</td>
<td>Metformin, Resveratrol</td>
</tr>
<tr>
<td class="label">TFEB activators</td>
<td>Genistein, Daidzein</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin (Sirolimus)</td>
<td>mTORC1 inhibitor</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>mTORC1 inhibitor</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>mTOR-independent</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>AMPK activator</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>mTOR-independent + [GSK-3β](/entities/gsk3-beta)</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>AMPK/SIRT1 activator</td>
</tr>
<tr>
<td class="label">Carbamazepine</td>
<td>mTOR-independent</td>
</tr>
<tr>
<td class="label">Nicotinamide</td>
<td>SIRT1 activator</td>
</tr>
<tr>
<td class="label">Genistein</td>
<td>TFEB activator</td>
</tr>
<tr>
<td class="label">Laquinimod</td>
<td>Immunomodulator</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT04629495</td>
<td>Rapamycin</td>
</tr>
<tr>
<td class="label">NCT05915091</td>
<td>Rapamycin</td>
</tr>
<tr>
<td class="label">NCT05119283</td>
<td>Trehalose</td>
</tr>
<tr>
<td class="label">NCT04644081</td>
<td>Trehalose</td>
</tr>
<tr>
<td class="label">NCT04833638</td>
<td>Trehalose</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT04534478</td>
<td>Trehalose</td>
</tr>
<tr>
<td class="label">NCT04200911</td>
<td>Rapamycin</td>
</tr>
<tr>
<td class="label">NCT02550349</td>
<td>Everolimus</td>
</tr>
</table>

[Autophagy](/entities/autophagy) inducers are therapeutic compounds that enhance cellular autophagy—the evolutionarily conserved process by which cells degrade and recycle misfolded proteins, damaged organelles, and protein aggregates. This therapeutic strategy directly addresses the accumulation of toxic protein aggregates that characterize neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). [@rubinsztein2012]

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Overview

Autophagy (specifically macroautophagy) involves the formation of double-membrane autophagosomes that engulf cellular debris and fuse with lysosomes for degradation. The autophagy-lysosomal pathway is crucial for neuronal health because post-mitotic [neurons](/entities/neurons) cannot dilute toxic proteins through cell division. [@nixon2013]

Compromised autophagy is a hallmark of neurodegeneration:

Impaired autophagosome formation in AD brains
Reduced lysosomal function in PD dopaminergic neurons
Mutant [huntingtin](/proteins/huntingtin-protein) disrupts autophagic flux in HD
[TDP-43](/mechanisms/tdp-43-proteinopathy) aggregation impairs autophagy in ALS

Mechanism of Action

Multiple molecular pathways regulate autophagy: [@harris2012]

mTORC1 inhibition: Direct or indirect inhibition of [mTOR](/entities/mtor) complex 1 activates the ULK1 kinase complex, initiating autophagosome nucleation
AMPK activation: Energy sensor AMPK promotes autophagy through ULK1 phosphorylation at Ser317 and Ser777
[TFEB](/entities/tfeb) activation: Transcription factor EB promotes expression of lysosomal and autophagy genes (CLEAR network)
Beclin-1 complex modulation: Enhanced VPS34 lipid kinase activity initiates vesicle nucleation
Autophagy receptor targeting: p62/SQSTM1 phosphorylation at Ser403 enhances selective autophagy of ubiquitinated aggregates

mTOR-Dependent vs mTOR-Independent Pathways

Disease-Specific Applications

Alzheimer's Disease

Autophagy induction addresses multiple AD pathologies: [@menzies2017]

[Aβ](/proteins/amyloid-beta) clearance: Enhanced macroautophagy promotes transcellular degradation of Aβ plaques
Mitophagy: Removal of damaged mitochondria reduces [ROS](/entities/reactive-oxygen-species) and restores neuronal bioenergetics
[Tau](/proteins/tau) clearance: Autophagy-lysosomal pathway clears hyperphosphorylated [tau](/proteins/tau) via p62-mediated selective autophagy
Neuroinflammation: Autophagy reduces [NLRP3](/entities/nlrp3-inflammasome) inflammasome activation in [microglia](/cell-types/microglia-neuroinflammation)

Clinical evidence: Rapamycin (Sirolimus) has shown cognitive benefit in small AD trials, with Phase II studies ongoing (NCT04629495). Everolimus (NCT02550349) demonstrated cognitive benefit in moderate AD.

Corticobasal Syndrome and Progressive Supranuclear palsy

Autophagy enhancement is particularly relevant to 4R-tauopathies including CBS and PSP, where:

mTORC1 hyperactivation is documented in PSP post-mortem brain tissue
4R-tau filaments are primarily cleared by macroautophagy (not proteasome)
TFEB dysfunction reduces lysosomal biogenesis in PSP brains
Autophagy-lysosomal deficiency confirmed with reduced cathepsin D and p62 accumulation

Rapamycin directly addresses mTORC1 hyperactivation and can clear 4R-tau aggregates via autophagy. The geroscience dosing (5-6 mg weekly) is well-tolerated with no immunosuppression at low intermittent doses.

Trehalose for 4R-Tauopathies

Trehalose shows particular promise for CBS/PSP due to its mTOR-independent mechanism:

Direct tau clearance: Enhanced autophagy removes hyperphosphorylated 4R-tau aggregates
TFEB activation: Promotes lysosomal biogenesis to compensate for PSP-related dysfunction
Anti-aggregation: Stabilizes native tau conformations, preventing seeding
Safety profile: Oral administration, GRAS status, well-tolerated in clinical trials

Clinical trials: NCT04833638 (CBD Phase 1) is evaluating trehalose specifically in corticobasal degeneration, making it directly relevant to this patient's differential diagnosis.

Rapamycin for 4R-Tauopathies

Rapamycin (Sirolimus) addresses the mTORC1 hyperactivation documented in PSP:

mTORC1 inhibition: Restores normal autophagy initiation
4R-tau clearance: Promotes macroautophagy-mediated clearance of 4R-tau filaments
Geroscience dosing: 5-6 mg weekly shows beneficial autophagy effects without immunosuppression
Combination potential: Synergizes with anti-tau immunotherapies (E2814, BIIB080) by enhancing aggregate clearance

Off-label consideration: Rapamycin is FDA-approved for transplant rejection. Off-label use for neurodegeneration requires monitoring lipids, blood counts, and infection signs.

Parkinson's Disease

PD particularly benefits from autophagy enhancement due to [α-synuclein](/proteins/alpha-synuclein) pathology: [@moors2020]

α-synuclein clearance: Autophagy degrades both monomeric and aggregated α-synuclein
Mitophagy protection: PINK1/Parkin pathway activation protects dopaminergic neurons
LRRK2 modulation: Autophagy inducers synergize with LRRK2 inhibitors
GCase enhancement: Autophagy improves glucocerebrosidase trafficking

Clinical evidence: Carbamazepine (NCT04643145) and trehalose (NCT02939460) have completed Phase I trials showing safety.

Huntington's Disease

HD is uniquely responsive to autophagy induction: [@sarkar2007]

mHTT clearance: Autophagy selectively targets mutant [huntingtin](/genes/htt) aggregates
Neuronal survival: Improved mitochondrial quality correlates with striatal neuron survival
Motor function: Trehalose improved rotarod performance in R6/2 mice

Clinical evidence: Laquinimod (NCT02221116) and trehalose (NCT04577370) have completed HD trials.

Amyotrophic Lateral Sclerosis

ALS involves TDP-43 and SOD1 aggregates amenable to autophagy: [@chen2023]

TDP-43 clearance: Autophagy removes cytoplasmic TDP-43 inclusions
SOD1 clearance: Enhanced autophagy accelerates mutant SOD1 turnover
Motor neuron protection: Autophagy preserves axonal homeostasis

Clinical evidence: Rapamycin has been explored in ALS (NCT02444737) with mixed results.

Key Drug Candidates

Clinical Trial Landscape

Active Trials (2025-2026)

CBS/PSP-Specific Considerations

Trehalose (NCT04833638): This is the most directly relevant trial for this patient's differential. CBD (corticobasal degeneration) shares pathological features with PSP as a 4R-tauopathy. Results from this trial will inform broader application to 4R-tauopathies.

Rapamycin: No ongoing PSP-specific trials. Off-label use is supported by the strong mechanistic rationale (mTORC1 hyperactivation in PSP) and safety data from other indications.

Recently Completed Trials

Therapeutic Implications

Autophagy induction offers disease-modifying potential: [@fleming2020]

Aggregate clearance: Direct removal of pathological protein deposits via selective autophagy
Neuroprotection: Mitochondrial quality control prevents [apoptosis](/entities/apoptosis)
Anti-inflammatory: Reduced NLRP3 inflammasome activation decreases neuroinflammation
Timing: Early intervention may prevent aggregate nucleation
Combination: Synergy with aggregation inhibitors (e.g., [tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors))

Biomarkers for Monitoring

LC3-II turnover: Western blot measuring autophagic flux
p62 levels: Decreasing p62 indicates successful aggregate clearance
Serum GDF-15: Biomarker of autophagy activation
Lysosomal function: Cathepsin D activity assays

Research Directions

Current research focuses on: [@song2019]

Brain-penetrant mTOR inhibitors: Derivatives with reduced immunosuppression
mTOR-independent enhancers: Trehalose, carbamazepine, verapamil
TFEB nuclear translocation: Gene therapy approaches (AAV-TFEB)
Autophagy receptor modulators: p62 activators
Combination therapies: Autophagy + aggregation inhibition + neuroprotection

Emerging Approaches

TFEB gene therapy: AAV-mediated TFEB overexpression in preclinical models
Autophagy-targeting antibodies: Anti-LC3 immunotherapies
Lysosomal enhancement: Galectin-3 inhibitors for damaged lysosome clearance

Safety and Limitations

Autophagy induction has important considerations:

Autophagy inhibition in cells: Essential normal cellular processes may be affected
Immunosuppression: mTOR inhibitors increase infection risk
Metabolic effects: Altered glucose and lipid metabolism
Timing window: Excessive autophagy may be detrimental
[Blood-brain barrier](/entities/blood-brain-barrier): Many candidates have limited CNS penetration

External Links

[ClinicalTrials.gov - Autophagy Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=autophagy)
[PubMed Autophagy Reviews](https://pubmed.ncbi.nlm.nih.gov/?term=autophagy+neurodegeneration+review)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Rubinsztein DC, et al, Autophagy and misfolded protein clearance in neurodegenerative diseases (2012)](https://pubmed.ncbi.nlm.nih.gov/22941104/)

[Nixon RA, The role of autophagy in neurodegenerative disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23921753/)

[Harris H, Rubinsztein DC, Control of autophagy as a therapy for neurodegenerative disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22249805/)

[Menzies FM, et al, Autophagy induction as a therapeutic strategy for neurodegenerative diseases (2017)](https://pubmed.ncbi.nlm.nih.gov/28340343/)

[Moors TE, et al, Therapeutic potential of autophagy-enhancing drugs in neurodegenerative proteinopathies (2020)](https://pubmed.ncbi.nlm.nih.gov/32877962/)

[Sarkar S, et al, Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteins (2007)](https://pubmed.ncbi.nlm.nih.gov/17210912/)

[Chen S, et al, Autophagy and ALS: Mechanisms and therapeutic targets (2023)](https://pubmed.ncbi.nlm.nih.gov/36774369/)

[Fleming A, et al, The different autophagy pathways in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32105645/)

[Song JX, et al, Trehalose, an autophagy inducer, ameliorates alpha-synuclein pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/30929545/)

[Piras A, Collin L, Grüninger F, et al, Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy (2016)](https://pubmed.ncbi.nlm.nih.gov/27074917/)

[Höglinger GU, Huppertz HJ, Wagenpfeil S, et al, Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial (2014)](https://pubmed.ncbi.nlm.nih.gov/24420726/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Autophagy Inducers in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-autophagy-inducers-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-autophagy-inducers-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4fe6ae5e3c94
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-autophagy-inducers-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

559

Outgoing

772

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Autophagy Inducers in Neurodegeneration

Autophagy Inducers in Neurodegeneration

Introduction

Autophagy Inducers in Neurodegeneration

Introduction

Pathway / Mechanism Diagram

Overview

Mechanism of Action

mTOR-Dependent vs mTOR-Independent Pathways

Disease-Specific Applications

Alzheimer's Disease

Corticobasal Syndrome and Progressive Supranuclear palsy

Trehalose for 4R-Tauopathies

Rapamycin for 4R-Tauopathies

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis

Key Drug Candidates

Clinical Trial Landscape

Active Trials (2025-2026)

CBS/PSP-Specific Considerations

Recently Completed Trials

Therapeutic Implications

Biomarkers for Monitoring

Research Directions

Emerging Approaches

Safety and Limitations

See Also

External Links

Allen Brain Atlas Resources

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Autophagy Inducers in Neurodegeneration

Autophagy Inducers in Neurodegeneration

Introduction

Autophagy Inducers in Neurodegeneration

Introduction

Pathway / Mechanism Diagram

Overview

Mechanism of Action

mTOR-Dependent vs mTOR-Independent Pathways

Disease-Specific Applications

Alzheimer's Disease

Corticobasal Syndrome and Progressive Supranuclear palsy

Trehalose for 4R-Tauopathies

Rapamycin for 4R-Tauopathies

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis

Key Drug Candidates

Clinical Trial Landscape

Active Trials (2025-2026)

CBS/PSP-Specific Considerations

Recently Completed Trials

Therapeutic Implications

Biomarkers for Monitoring

Research Directions

Emerging Approaches

Safety and Limitations

See Also

External Links

Allen Brain Atlas Resources

References

Related Hypotheses

Pathway Diagram

💬 Discussion